Effective alternative to TNF inhibitors

Cutaneous Crohn’s disease (CCD) is a granulomatous skin disease that is not associated with the gastrointestinal tract. It rarely correlates with intestinal disease and often requires separate treatment. Although interleukin (IL)-12/23 and IL-23 inhibitors are FDA-approved for intestinal Crohn’s disease, there are limited data on CCD.